8-K: Tivic Health Systems Announces $10 Million Equity Distribution Agreement and CFO Transition

Tivic Health Systems has entered into an agreement to sell up to $10 million of its common stock and appointed a new interim CFO, effective October 1, 2024.

Summary

• Tivic Health Systems has entered into an Equity Distribution Agreement with Maxim Group LLC to sell up to $10 million of its common stock.
• The company will pay Maxim a 3.0% commission on the gross proceeds from each sale, plus up to $40,000 in fees and $5,000 for each bringdown.
• The agreement will terminate upon the sale of all $10 million in shares, 24 months from the agreement date, mutual termination, or as otherwise permitted.
• The shares will be sold under a prospectus supplement filed on September 13, 2024, related to an existing shelf registration statement.
• Kimberly Bambach has resigned as interim CFO, effective October 1, 2024, and will continue in an advisory role.
• Lisa Wolf has been appointed as the new interim CFO, effective October 1, 2024, and will be paid $275 per hour for her services.
• Ms. Wolf has over 30 years of experience in public accounting and private industry and has been supporting Tivic's accounting and SEC reporting since June 2022.

Sentiment

Score: 6

Explanation: The document is neutral to slightly positive. The capital raise is a positive step for the company's growth, but the CFO transition and associated costs introduce some uncertainty. The company is taking steps to ensure a smooth transition.

Positives

• The Equity Distribution Agreement provides Tivic Health with a mechanism to raise up to $10 million in capital.
• Lisa Wolf brings over 30 years of financial leadership experience and has been involved with the company's finances for over two years.
• Kimberly Bambach will continue to provide advisory services, ensuring a smooth transition and continued access to her expertise.

Negatives

• The company will incur a 3.0% commission on all shares sold, plus additional fees and expenses.
• There is no guarantee that the company will sell all or any of the shares under the agreement.
• The company is undergoing a transition in its CFO role, which could create some short-term instability.

Risks

• The company may not be able to sell all of the shares under the agreement, or at the desired price.
• The company's stock price could be negatively impacted by the sale of new shares.
• The transition in CFO roles could create some short-term operational challenges.
• The company's future performance is subject to various risks and uncertainties, as detailed in their SEC filings.

Future Outlook

The company intends to use the net proceeds from the sale of shares for general corporate purposes. The company is also focused on its next phase of growth in bioelectronic therapeutics.

Management Comments

• Jennifer Ernst, CEO of Tivic, stated she is delighted to have Lisa Wolf taking on an even more pivotal role and looks forward to working with her to lead the company into its next phase of growth.
• Jennifer Ernst expressed gratitude for Kimberly Bambach's contributions and is pleased she will continue in an advisory capacity.

Industry Context

The company is operating in the health tech sector, specifically in bioelectronic medicine, which is a growing field. The capital raise will allow the company to further develop and commercialize its technology.

Comparison to Industry Standards

• The use of an at-the-market (ATM) offering is a common method for companies to raise capital, particularly in the biotech and health tech sectors.
• The 3% commission is within the typical range for ATM offerings.
• The appointment of an interim CFO is not uncommon during periods of transition, and the hourly rate is consistent with market rates for experienced financial consultants.
• Comparable companies in the bioelectronic medicine space include ElectroCore and Nevro, which also utilize similar financing strategies.

Management Changes

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• Employees will see a change in leadership in the finance department.
• Customers and suppliers are unlikely to be directly impacted by these changes.

Next Steps

• The company will begin selling shares of common stock through Maxim Group LLC.
• Lisa Wolf will assume the role of interim CFO on October 1, 2024.
• Kimberly Bambach will transition to an advisory role.

Key Dates

Keywords

Equity Distribution Agreement, Common Stock, Capital Raise, Interim CFO, Maxim Group LLC, Lisa Wolf, Kimberly Bambach, At-the-market offering, Financial Officer, Bioelectronic Medicine